| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9aa4d7ac4628b72dd48dd67f6a436fc9 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2018-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1893c22d11a5716487975e79672ed736
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cf250f0cdb42cdeffb9237f8098bb25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f2285c3c3d230dbd9eef8cc0f66c77e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5949f117faf4683e7cb2d34385bd06c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0dc0b929a2d69b1a1ac3e1940e28b243
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_344ab33f5b5d3d96d4d4a7c17dde6130
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a85426d5f6826dfc7f5446d8afd5097f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e7943d5c134a5906d7e0b9a2cc8a164
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0927d226a6e72a1982e87efb1ac650d |
| publicationDate |
2020-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3719012-A1 |
| titleOfInvention |
Uracil compound as c-met/axl inhibitor |
| abstract |
Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023031683-A1 |
| priorityDate |
2017-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |